Referenze
1. Headache Classification Committee of the International Headache Society
(IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia.
2018;38(1):1-211.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional,
and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195
countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet.
2017:390(10100):1211-1259.
3. Saxena S, Dua T, Saraceno B, et al. Atlas of Headache Disorders and Resources
in the World. World Health Organization. 2011.
4. American Migraine Foundation. Accesso: 13 novembre 2020.
https://americanigrainefoundation.org/resource-library/understandmigrainepreventivetreatments/.
5. Buse DC,
Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related
functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422-435.
6.
Rosenberg J. 86 million workdays lost annually to migraine in the UK. AJMC. Accesso: 18 novembre
2020.https://www.ajmc.com/view/86-million-workdays-lostannually-to- migraine-in-the-uk.
7. Serrano D,
Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic
migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Value Health. 2013;16(1):31-38.
8. Seng EK et al; Headache. 2019 Feb;59(2):224-234.
9. Stang PE, Crown
WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care.
2004;10(5):313-320.
10. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between
episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86-92.
11. Lipton RB. Tracing
transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(Issue 5,
Supplement 1):S3-S7.
12. Bigal M, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine
medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache.
2008;48(8):1157-1168.
13. Blumenfeld A, Varon S, Wilcox T, et al. Disability, HRQoL and resource use among
chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia.
2010;31(3):301-315.
14. Nicholson R, Buse D, Andrasik F, Lipton RB. Nonpharmacologic treatments for
migraine and tension-type headache: how to choose and when to use. Curr Treat Options Neurol.
2010;13(1):28-40.
15. Clemow D, Johnson K, Hochstetler H, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan
mechanism of action – review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1). doi:
10.1186/s10194-020- 01132-3.
16. Acupuncture. The Migraine Trust. Accesso: 13 novembre 2020.
https://www.migrainetrust.org/living-with-migraine/treatments/acute-medicines/.
17. Exercise. The Migraine
Trust. Accesso: 13 novembre 2020.
https://www.migrainetrust.org/living-with-migraine/coping-managing/exercise/.
18. Sleep and Migraine. The
Migraine Trust. Accesso: 13 novembre 2020.
https://www.migrainetrust.org/living-with-migraine/coping-managing/sleep/.
19. Lipton R, Bigal M, Diamond
M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-
349.